127 related articles for article (PubMed ID: 2214168)
1. [Beneficial characteristics of protease inhibitor as an anticoagulant for extracorporeal circulation].
Akizawa T
Rinsho Ketsueki; 1990 Jun; 31(6):782-6. PubMed ID: 2214168
[TBL] [Abstract][Full Text] [Related]
2. [Pharmacokinetics studies of nafamostat mesilate (FUT), a synthetic protease inhibitor, which has been used for the treatments of DIC and acute pancreatitis, and as an anticoagulant in extracorporeal circulation].
Tsukagoshi S
Gan To Kagaku Ryoho; 2000 May; 27(5):767-74. PubMed ID: 10832450
[TBL] [Abstract][Full Text] [Related]
3. [Effectiveness of FUT-175, protease inhibitor, as an anticoagulant to hemodialysis].
Pak K; Shirasu A; Okino K; Sako H; Nakane Y; Umemura K; Maeda S; Tomoyoshi T
Hinyokika Kiyo; 1988 Jun; 34(6):1077-81. PubMed ID: 3223453
[TBL] [Abstract][Full Text] [Related]
4. The influence of a serine protease inhibitor, nafamostat mesilate, on plasma coagulation, and platelet activation during experimental Extracorporeal Life Support (ECLS).
Mellgren K; Skogby M; Friberg LG; Tengborn L; Wadenvik H
Thromb Haemost; 1998 Feb; 79(2):342-7. PubMed ID: 9493588
[TBL] [Abstract][Full Text] [Related]
5. Plasma collection using nafamostat mesilate and dipyridamole as an anticoagulant.
Hiraishi M; Yamazaki Z; Ichikawa K; Kanai F; Idezuki Y; Onishi K; Takahama T; Inoue N
Int J Artif Organs; 1988 May; 11(3):212-6. PubMed ID: 3403059
[TBL] [Abstract][Full Text] [Related]
6. The anticoagulant and hemorrhagic effects of DHG, a new depolymerized holothurian glycosaminoglycan, on experimental hemodialysis in dogs.
Minamiguchi K; Kitazato KT; Sasaki E; Nagase H; Kitazato K
Thromb Haemost; 1997 Jun; 77(6):1148-53. PubMed ID: 9241748
[TBL] [Abstract][Full Text] [Related]
7. Comparative clinical trial of regional anticoagulation for hemodialysis.
Akizawa T; Kitaoka T; Sato M; Koshikawa S; Hirasawa Y; Kazama M; Mimura N; Ota K
ASAIO Trans; 1988; 34(3):176-8. PubMed ID: 3058171
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic plasmapheresis for post-operative hepatic failure.
Tani T; Endo Y; Yoshioka T; Aoki H; Matsuda K; Numa K; Hanasawa K; Kodama M
Prog Clin Biol Res; 1990; 337():213-20. PubMed ID: 2352979
[TBL] [Abstract][Full Text] [Related]
9. Effects of nafamostat mesilate on ADP-induced platelet aggregation and disaggregation in hemodialysis patients.
Miyata M; Shirakawa T; Acharya B; Terao S; Gotoh A
ASAIO J; 2006; 52(3):272-5. PubMed ID: 16760715
[TBL] [Abstract][Full Text] [Related]
10. Application of a new anticoagulant (Nafamostat Mesilate) to control hemorrhagic complications during extracorporeal membrane oxygenation--a preliminary report.
Nagaya M; Futamura M; Kato J; Niimi N; Fukuta S
J Pediatr Surg; 1997 Apr; 32(4):531-5. PubMed ID: 9126748
[TBL] [Abstract][Full Text] [Related]
11. [Pharmacological studies of FUT-175, nafamstat mesilate. IV. Effects on coagulation, platelets and fibrinolysis].
Koshiyama Y; Ozeki M; Motoyoshi A; Fujita M; Iwaki M; Aoyama T
Nihon Yakurigaku Zasshi; 1984 Nov; 84(5):417-28. PubMed ID: 6519580
[TBL] [Abstract][Full Text] [Related]
12. [Molecular specificity of nafamostat mesilate (FUT), a drug used for the treatments of DIC and acute pancreatitis and as an anticoagulant--the pharmacodynamics and pharmacological action].
Tsukagoshi S
Gan To Kagaku Ryoho; 2001 Sep; 28(9):1237-43. PubMed ID: 11579633
[TBL] [Abstract][Full Text] [Related]
13. Nafamostat mesilate, a broad spectrum protease inhibitor, modulates platelet, neutrophil and contact activation in simulated extracorporeal circulation.
Sundaram S; Gikakis N; Hack CE; Niewiarowski S; Edmunds LH; Koneti Rao A; Sun L; Cooper SL; Colman RW
Thromb Haemost; 1996 Jan; 75(1):76-82. PubMed ID: 8713783
[TBL] [Abstract][Full Text] [Related]
14. Gabexate mesilate (Foy) as an anticoagulant in extracorporeal circulation in dogs and sheep.
Oedekoven B; Bey R; Mottaghy K; Schmid-Schönbein H
Thromb Haemost; 1984 Dec; 52(3):329-32. PubMed ID: 6442472
[TBL] [Abstract][Full Text] [Related]
15. Nafamostat mesilate: a regional anticoagulant for hemodialysis in patients at high risk for bleeding.
Akizawa T; Koshikawa S; Ota K; Kazama M; Mimura N; Hirasawa Y
Nephron; 1993; 64(3):376-81. PubMed ID: 8341382
[TBL] [Abstract][Full Text] [Related]
16. Anticoagulation with nafamostat mesilate, a synthetic protease inhibitor, in hemodialysis patients with a bleeding risk.
Matsuo T; Kario K; Nakao K; Yamada T; Matsuo M
Haemostasis; 1993; 23(3):135-41. PubMed ID: 8276316
[TBL] [Abstract][Full Text] [Related]
17. Clinical evaluation of nafamstat mesilate (FUT 175). A new anticoagulant for plasmapheresis.
Hosokawa S; Oyamaguchi A; Yoshida O
ASAIO J; 1992; 38(1):59-60. PubMed ID: 1554918
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of nafamostat mesilate as a regional anticoagulant in experimental direct hemoperfusion and in plasma exchange on humans.
Abe H; Tani T; Numa K; Endo Y; Yoshioka T; Kodama M
Artif Organs; 1992 Apr; 16(2):206-8. PubMed ID: 10078246
[TBL] [Abstract][Full Text] [Related]
19. Adsorption of nafamostat mesilate by hemodialysis membranes.
Inagaki O; Nishian Y; Iwaki R; Nakagawa K; Takamitsu Y; Fujita Y
Artif Organs; 1992 Dec; 16(6):553-8. PubMed ID: 1482323
[TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamics of FUT-175 anticoagulant in adsorbent plasma perfusion.
Yamazaki Z; Hiraishi M; Kanai F; Takahama T; Idezuki Y; Inoue N
ASAIO Trans; 1989; 35(3):567-9. PubMed ID: 2688721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
